BRPI0810561A2 - methods and compositions for treating and monitoring treatment of il-13 associated disorders. - Google Patents
methods and compositions for treating and monitoring treatment of il-13 associated disorders.Info
- Publication number
- BRPI0810561A2 BRPI0810561A2 BRPI0810561A BRPI0810561A BRPI0810561A2 BR PI0810561 A2 BRPI0810561 A2 BR PI0810561A2 BR PI0810561 A BRPI0810561 A BR PI0810561A BR PI0810561 A BRPI0810561 A BR PI0810561A BR PI0810561 A2 BRPI0810561 A2 BR PI0810561A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- treating
- methods
- associated disorders
- monitoring treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92607807P | 2007-04-23 | 2007-04-23 | |
US92593207P | 2007-04-23 | 2007-04-23 | |
PCT/US2008/061130 WO2008131376A2 (en) | 2007-04-23 | 2008-04-22 | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0810561A2 true BRPI0810561A2 (en) | 2019-09-24 |
Family
ID=39689094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0810561A BRPI0810561A2 (en) | 2007-04-23 | 2008-04-22 | methods and compositions for treating and monitoring treatment of il-13 associated disorders. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090068195A1 (en) |
EP (1) | EP2137215A2 (en) |
JP (1) | JP2010527916A (en) |
CN (1) | CN101977935A (en) |
AR (1) | AR066240A1 (en) |
BR (1) | BRPI0810561A2 (en) |
CA (1) | CA2685123A1 (en) |
CL (1) | CL2008001182A1 (en) |
MX (1) | MX2009011366A (en) |
PA (1) | PA8778101A1 (en) |
PE (1) | PE20090154A1 (en) |
RU (1) | RU2009140134A (en) |
TW (1) | TW200848429A (en) |
WO (1) | WO2008131376A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (en) | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
GB0509512D0 (en) * | 2005-05-10 | 2005-06-15 | Novartis Ag | Organic compounds |
CA2722466A1 (en) * | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
CA2725666A1 (en) * | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
AU2009256250B2 (en) * | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
NZ590074A (en) * | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
UY32808A (en) * | 2009-07-29 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME |
IN2012DN02737A (en) * | 2009-09-01 | 2015-09-11 | Abbott Lab | |
EP2486940B1 (en) * | 2009-10-08 | 2017-10-04 | Aeon Medix Inc. | Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof |
KR20140015139A (en) * | 2009-10-15 | 2014-02-06 | 애브비 인코포레이티드 | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CN103492583A (en) * | 2010-11-02 | 2014-01-01 | Abbvie公司 | Dual variable domain immunoglobulins and uses thereof |
WO2012078688A2 (en) | 2010-12-06 | 2012-06-14 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
BR112013013460A8 (en) * | 2010-12-16 | 2019-02-12 | Genentech Inc | methods for identifying an asthma patient, method for monitoring an asthma patient, use of a total periostin detection kit, total periostin measurement kit, use of an anti-il-13 antibody, use of a therapeutically amount lebrikizumab therapy, use of a th2 pathway inhibitor, adverse event evaluation method, anti-periostin antibody, and total periostin test |
SG10201606950RA (en) * | 2011-03-31 | 2016-10-28 | Genentech Inc | Methods of administering beta7 integrin antagonists |
SG10201505454SA (en) * | 2011-07-13 | 2015-09-29 | Abbvie Inc | Methods and compositions for treating asthma using anti-il-13 antibodies |
UY34558A (en) | 2011-12-30 | 2013-07-31 | Abbvie Inc | DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17 |
CN107099581B (en) * | 2012-03-27 | 2021-07-13 | 弗·哈夫曼-拉罗切有限公司 | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
AU2013271338B2 (en) * | 2012-06-05 | 2018-05-24 | The Australian National University | Vaccination with interleukin-4 antagonists |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
RU2740672C2 (en) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Structures having sirp-alpha domain or its version |
MA45324A (en) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | POLYTHERAPY USING ADC-LIV1 AND CHEMOTHERAPEUTIC AGENT |
CN109705217B (en) * | 2017-10-25 | 2020-09-11 | 北京智仁美博生物科技有限公司 | anti-IL-13 antibodies and uses thereof |
JP2021534769A (en) * | 2018-08-31 | 2021-12-16 | エーエルエックス オンコロジー インコーポレイテッド | Decoy polypeptide |
AU2020247175A1 (en) * | 2019-03-26 | 2021-10-14 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-IL-13R antibody or binding fragment thereof |
WO2020243338A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5246701A (en) * | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
DK0506574T3 (en) * | 1991-03-29 | 1996-04-09 | Sanofi Sa | Protein with cytokine-type activity, recombinant DNA encoding this protein, cells and transformed microorganisms |
JP4124480B2 (en) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
WO1995006481A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (en) * | 1995-12-06 | 1997-06-13 | Sanofi Sa | IL-13 RECEPTOR POLYPEPTIDE |
US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
US6387615B2 (en) * | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
BR9813365A (en) * | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
AU780031B2 (en) * | 1998-12-14 | 2005-02-24 | Genetics Institute, Llc | Cytokine receptor chain |
US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0004016D0 (en) * | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
WO2001077332A2 (en) * | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
IL156618A0 (en) * | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
AUPR544401A0 (en) * | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
IL159215A0 (en) * | 2001-06-07 | 2004-06-01 | Wyeth Corp | A solution of interleukin-13 and methods utilizing the same |
US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US20040248260A1 (en) * | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US20050154192A1 (en) * | 2001-11-27 | 2005-07-14 | Kamon Shirakawa | Anti-il13 receptor alpha1 neutralizing antibody |
WO2003047632A1 (en) * | 2001-12-04 | 2003-06-12 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
WO2003080675A2 (en) * | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
AU2003243189B2 (en) * | 2002-05-01 | 2008-01-24 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
CA2489540A1 (en) * | 2002-06-14 | 2003-12-31 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer | Methods of treating and preventing colitis involving il-13 and nk-t cells |
JP2004121218A (en) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | Method for testing bronchial asthma or chronic obstructive pulmonary disease |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
SG10201900535UA (en) * | 2003-12-23 | 2019-02-27 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
KR20060127415A (en) * | 2003-12-24 | 2006-12-12 | 와이어쓰 | Methods of treating asthma |
US20050186146A1 (en) * | 2004-02-12 | 2005-08-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
EP1720573A4 (en) * | 2004-02-27 | 2008-04-02 | Centocor Inc | Methods and compositions for treating il-13 related pathologies |
US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (en) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
RU2009120202A (en) * | 2006-12-11 | 2011-01-20 | Вайет (Us) | METHODS AND COMPOSITIONS FOR TREATMENT AND MONITORING OF TREATMENT ASSOCIATED WITH IL-13 DISORDERS |
-
2008
- 2008-04-22 TW TW097114612A patent/TW200848429A/en unknown
- 2008-04-22 MX MX2009011366A patent/MX2009011366A/en not_active Application Discontinuation
- 2008-04-22 EP EP08746533A patent/EP2137215A2/en not_active Withdrawn
- 2008-04-22 CN CN2008800213299A patent/CN101977935A/en active Pending
- 2008-04-22 WO PCT/US2008/061130 patent/WO2008131376A2/en active Application Filing
- 2008-04-22 BR BRPI0810561A patent/BRPI0810561A2/en not_active IP Right Cessation
- 2008-04-22 US US12/107,456 patent/US20090068195A1/en not_active Abandoned
- 2008-04-22 JP JP2010506427A patent/JP2010527916A/en not_active Withdrawn
- 2008-04-22 CA CA002685123A patent/CA2685123A1/en not_active Abandoned
- 2008-04-22 RU RU2009140134/10A patent/RU2009140134A/en not_active Application Discontinuation
- 2008-04-22 AR ARP080101679A patent/AR066240A1/en unknown
- 2008-04-23 PE PE2008000699A patent/PE20090154A1/en not_active Application Discontinuation
- 2008-04-23 PA PA20088778101A patent/PA8778101A1/en unknown
- 2008-04-23 CL CL2008001182A patent/CL2008001182A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2009140134A (en) | 2011-05-27 |
TW200848429A (en) | 2008-12-16 |
PE20090154A1 (en) | 2009-03-31 |
CN101977935A (en) | 2011-02-16 |
WO2008131376A2 (en) | 2008-10-30 |
CL2008001182A1 (en) | 2009-01-16 |
JP2010527916A (en) | 2010-08-19 |
AR066240A1 (en) | 2009-08-05 |
EP2137215A2 (en) | 2009-12-30 |
US20090068195A1 (en) | 2009-03-12 |
CA2685123A1 (en) | 2008-10-30 |
WO2008131376A3 (en) | 2009-02-05 |
MX2009011366A (en) | 2009-11-05 |
PA8778101A1 (en) | 2008-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0810561A2 (en) | methods and compositions for treating and monitoring treatment of il-13 associated disorders. | |
BRPI0921237A2 (en) | methods and compositions for the treatment of complement-associated disorders | |
BRPI0911757A2 (en) | compositions and methods for treating digestive disorders. | |
BRPI0919920A2 (en) | compounds for treating ophthalmic diseases and disorders | |
BRPI0918670A2 (en) | compositions and methods for the treatment of ige-mediated disorders | |
BRPI0812767A2 (en) | C3B ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENTARY DISORDERS | |
BRPI0813725A2 (en) | METHODS AND COMPOSITIONS FOR DISEASE TREATMENT | |
BRPI0819678A2 (en) | method for treating cmt and related disorders | |
BRPI0819241A2 (en) | Amine-derived compounds for the treatment of ophthalmic disorders and diseases | |
BRPI0919195A2 (en) | Methods and Apparatus for the Treatment of Ear, Nose, and Throat Disorders | |
DK2350416T4 (en) | MULTIPLE RUDE AT LEAST ONE ANTIREFLECT TREATMENT AND APPLICATION OF ANTIREFLECT MULTIPLE RUDE TREATMENT | |
BRPI0908154A2 (en) | Methods for the treatment and prevention of age-related retinal dysfunctions | |
BRPI0813553A2 (en) | pharmaceutical compositions and methods for treating dry eye disorders | |
BRPI0917130A2 (en) | biomarkers for anti-tnf treatment of ulcerative colitis and related disorders | |
IL202611A0 (en) | Methods of treating serotonin-mediated diseases and disorders | |
BRPI0909627A2 (en) | methods, compositions and kits for treating pain and itching | |
BRPI0916323A2 (en) | controlled release antimicrobial compositions and methods for treating ear disorders | |
DK2726511T3 (en) | COMPOSITIONS, APPLICATIONS AND PROCEDURES FOR TREATING TREATMENT DISEASES AND DISORDERS | |
BRPI0818732A2 (en) | PROSTAGLANDINE ANALOG COMPOSITIONS AND METHODS FOR TREATING EPITELY RELATED CONDITIONS. | |
BRPI0919288A2 (en) | combination therapy for treatment of diabetes and related conditions. | |
BRPI0921321A2 (en) | methods for the treatment of tumors and tumors | |
BRPI0807987A2 (en) | COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS. | |
BRPI0814941A2 (en) | COMPOSITION OF SEED TREATMENT, AND, SEED TREATMENT METHOD. | |
BRPI0816712A2 (en) | interval therapy for the treatment of tinnitus | |
BRPI0911612A2 (en) | compositions and methods for the treatment of multiple sclerosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |